Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (132)	$ (696)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sale of in process research and development	(445)	(50)
Stock-based compensation expense	20	208
Changes in operating assets and liabilities:
Prepaid expenses and other assets	201	187
Accounts payable, accrued expenses and other	2	(86)
Net cash used in operating activities	(354)	(437)
Cash flows from investing activities
Proceeds from sale of in process research and development	445	50
Net cash provided by investing activities	445	50
Cash flows from financing activities
Proceeds from exercise of stock options		239
Net cash provided by financing activities		239
Net increase (decrease) in cash and cash equivalents	91	(148)
Cash and cash equivalents, beginning of period	14,203	14,038
Cash and cash equivalents, end of period	$ 14,294	$ 13,890